Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -173.14% is 69% below its 5-year average of -102.27%, around the middle of its 5-year range (-234.95%–-56.04%).
8.92% below its 12-month average of -158.95%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -22.06%.
RETURN ON ASSETS (ROA)
-173.14%
RETURN ON ASSETS (ROA) AVG TTM
-158.95%
RETURN ON ASSETS (ROA) AVG 3Y
-120.45%
RETURN ON ASSETS (ROA) AVG 5Y
-102.27%
RETURN ON ASSETS (ROA) AVG 10Y
-120.35%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-8.92%
CURRENT VS 3Y AVG
-43.74%
CURRENT VS 5Y AVG
-69.29%
CURRENT VS 10Y AVG
-43.86%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-437.03%
vs the sector median at left
Quantum BioPharma Ltd.
Market Cap
$19.77M
Return on Assets (ROA)
-173.14%
TTM Avg
-158.95%
3Y Avg
-120.45%
5Y Avg
-102.27%
Market Cap
$19.42M
Return on Assets (ROA)
-393.39%
TTM Avg
-225.59%
3Y Avg
-343.91%
5Y Avg
-343.91%
Market Cap
$20.53M
Return on Assets (ROA)
-188.98%
TTM Avg
-90.06%
3Y Avg
-67.42%
5Y Avg
-51.71%
Market Cap
$18.65M
Return on Assets (ROA)
-64.55%
TTM Avg
-0.45%
3Y Avg
-55.72%
5Y Avg
-45.67%
Market Cap
$18.41M
Return on Assets (ROA)
-15.04%
TTM Avg
-19.94%
3Y Avg
-19.35%
5Y Avg
-18.92%
Market Cap
$18.30M
Return on Assets (ROA)
-548.74%
TTM Avg
-346.44%
3Y Avg
-242.08%
5Y Avg
-167.09%
Market Cap
$22.00M
Return on Assets (ROA)
-13.57%
TTM Avg
-12.25%
3Y Avg
-12.55%
5Y Avg
-25.19%
Market Cap
$17.39M
Return on Assets (ROA)
-39.68%
TTM Avg
-29.52%
3Y Avg
-26.86%
5Y Avg
-20.28%
Market Cap
$17.31M
Return on Assets (ROA)
-49.72%
TTM Avg
-28.29%
3Y Avg
-39.08%
5Y Avg
-40.04%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quantum BioPharma Ltd. (QNTM) | $19.77M | -173.14% | -158.95% | -120.45% | -102.27% |
| Actuate Therapeutics Inc (ACTU)vs › | $19.42M | -393.39% | -225.59% | -343.91% | -343.91% |
| NextCure, Inc. (NXTC)vs › | $20.53M | -188.98% | -90.06% | -67.42% | -51.71% |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.65M | -64.55% | -0.45% | -55.72% | -45.67% |
| P3 Health Partners Inc. (PIII)vs › | $18.41M | -15.04% | -19.94% | -19.35% | -18.92% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.30M | -548.74% | -346.44% | -242.08% | -167.09% |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.00M | -13.57% | -12.25% | -12.55% | -25.19% |
| Cosmos Health Inc. (COSM)vs › | $17.39M | -39.68% | -29.52% | -26.86% | -20.28% |
| Lipocine Inc. (LPCN)vs › | $17.31M | -49.72% | -28.29% | -39.08% | -40.04% |
| Modular Medical, Inc. (MODD)vs › | $22.25M | -228.73% | -145.44% | -152.25% | -187.73% |
ROA
-173.1%
ROE
-313.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -234.95% |
| 2024-12-31 | -82.96% |
| 2023-12-31 | -102.45% |
| 2022-12-31 | -61.46% |
| 2021-12-31 | -56.04% |
| 2020-12-31 | -75.77% |
| 2019-12-31 | -90.54% |
| 2018-12-31 | -58.43% |
| 2017-12-31 | -25.76% |
| 2016-08-31 | -415.13% |
| 2015-08-31 | -1518.52% |
